Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 33
2023 40
2024 15

Text availability

Article attribute

Article type

Publication date

Related Articles by Review for PMID: 38696627

90 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab (Jemperli): CADTH Reimbursement Recommendation: Indication: Monotherapy for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. PMID: 38696627 Free Books & Documents. Review.
Atezolizumab (Tecentriq): CADTH Reimbursement Recommendation: Indication: In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. PMID: 38696640 Free Books & Documents. Review.
Tepotinib (Tepmetko): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with locally advanced unresectable metastatic non–small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. PMID: 38696639 Free Books & Documents. Review.
Pembrolizumab (Keytruda) in Combination With Lenvatinib (Lenvima): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. PMID: 38696635 Free Books & Documents. Review.
Fidanacogene Elaparvovec (Beqvez): CADTH Reimbursement Recommendation: Indication: For the treatment of adults (aged 18 years or older) with moderately severe to severe hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74 [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: SG0802. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: SG0802. PMID: 38648311 Free Books & Documents. Review.
Treosulfan (Trecondyv): CADTH Reimbursement Recommendation: Indication: Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0324. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0324. PMID: 38648307 Free Books & Documents. Review.
Sotorasib (Lumakras): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Kirsten rat sarcoma viral oncogene homologue (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) who have received at least one prior systemic therapy [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0300. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0300. PMID: 38648301 Free Books & Documents. Review.
Trifluridine-Tipiracil (Lonsurf): CADTH Reimbursement Recommendation: Indication: In combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have previously been treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0330. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0330. PMID: 38648298 Free Books & Documents. Review.
Nivolumab (Opdivo): CADTH Reimbursement Recommendation: Indication: As a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct. PMID: 38620390 Free Books & Documents. Review.
90 results
-